{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:41:02Z","timestamp":1781336462712,"version":"3.54.1"},"reference-count":53,"publisher":"American Chemical Society (ACS)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol. Pharmaceutics"],"published-print":{"date-parts":[[2017,10,2]]},"DOI":"10.1021\/acs.molpharmaceut.7b00257","type":"journal-article","created":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T15:44:27Z","timestamp":1504799067000},"page":"3258-3268","source":"Crossref","is-referenced-by-count":28,"title":["Brain Accumulation of Ponatinib and Its Active Metabolite,\n                    <i>N<\/i>\n                    -Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP\/ABCB1) and Breast Cancer Resistance Protein (BCRP\/ABCG2)"],"prefix":"10.1021","volume":"14","author":[{"given":"Anita","family":"Kort","sequence":"first","affiliation":[{"name":"Division\rof Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan\r121, 1066 CX Amsterdam, The Netherlands"},{"name":"Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute\/Slotervaart Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9094-5814","authenticated-orcid":true,"given":"St\u00e9phanie","family":"van Hoppe","sequence":"additional","affiliation":[{"name":"Division\rof Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan\r121, 1066 CX Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf W.","family":"Sparidans","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology & Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Wagenaar","sequence":"additional","affiliation":[{"name":"Division\rof Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan\r121, 1066 CX Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology & Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands"},{"name":"Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute\/Slotervaart Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands"},{"name":"Department\rof Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan\r121, 1066 CX Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred H.","family":"Schinkel","sequence":"additional","affiliation":[{"name":"Division\rof Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan\r121, 1066 CX Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2017,9,19]]},"reference":[{"key":"ref1\/cit1","unstructured":"Center for Drug valuation and Research of the U.S. Department of Health and Human Services Food and Drug Administration, 203469Orig1s000; 2012; Available from:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203469Orig1s000ClinPharmR.pdf."},{"key":"ref2\/cit2","unstructured":"European Medicines Agency. Science Medicines Health, Assessment report Iclusig; 2013; Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002695\/WC500145648.pdf."},{"key":"ref3\/cit3","unstructured":"FDA Drug Safety Communication. U.S. Food and Drug Administration, \u201cFDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales\u201d; 2013; Available from:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm373040.htm."},{"key":"ref4\/cit4","unstructured":"FDA Drug Safety Communication. U.S. Food and Drug Administration, \u201cIclusig (Ponatinib): Drug Safety Communication - Increased Reports Of Serious Blood Clots In Arteries And Veins\u201d; 2013; Available from:http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm370971.htm."},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0450"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2013.06.025"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1397"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.06.029"},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-1044"},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.130"},{"key":"ref12\/cit12","unstructured":"Novartis Pharmaceuticals Corporation, Gleevec [prescribing information]; 2004; Available from:https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/gleevec_tabs.pdf."},{"key":"ref13\/cit13","unstructured":"Novartis Pharmaceuticals, Tasigna [package insert]; 2014; Available from:https:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/tasigna.pdf."},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.025932"},{"key":"ref15\/cit15","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010387427"},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2511-z"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1039\/C6RA09985H"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3240-x"},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118699"},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2008.08.007"},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2006.07.020"},{"key":"ref22\/cit22","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0040-2"},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0302"},{"key":"ref24\/cit24","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.35"},{"key":"ref25\/cit25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.1990"},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.109"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.04.049"},{"key":"ref29\/cit29","doi-asserted-by":"publisher","DOI":"10.1021\/mp3003144"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.8.4028"},{"key":"ref31\/cit31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202607599"},{"key":"ref32\/cit32","doi-asserted-by":"publisher","DOI":"10.1038\/nm1186"},{"key":"ref33\/cit33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2915"},{"key":"ref34\/cit34","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.045260"},{"key":"ref35\/cit35","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.037317"},{"key":"ref36\/cit36","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1609-7"},{"key":"ref37\/cit37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404692"},{"key":"ref38\/cit38","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.024646"},{"key":"ref39\/cit39","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.167601"},{"key":"ref40\/cit40","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.162321"},{"key":"ref41\/cit41","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26000"},{"key":"ref42\/cit42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2253"},{"key":"ref43\/cit43","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-008-9138-z"},{"key":"ref44\/cit44","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-9135-x"},{"key":"ref45\/cit45","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.362"},{"key":"ref46\/cit46","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-013-1124-2"},{"key":"ref47\/cit47","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics6010097"},{"key":"ref48\/cit48","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0387-y"},{"key":"ref49\/cit49","doi-asserted-by":"publisher","DOI":"10.1124\/mol.107.043869"},{"key":"ref50\/cit50","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.5932"},{"key":"ref51\/cit51","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2617-y"},{"key":"ref52\/cit52","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.09.030"},{"key":"ref53\/cit53","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14222"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.7b00257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T05:19:34Z","timestamp":1682140774000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.molpharmaceut.7b00257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,19]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10,2]]}},"alternative-id":["10.1021\/acs.molpharmaceut.7b00257"],"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00257","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.730917969.793569212","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.730917969.793536737","asserted-by":"object"}]},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,19]]}}}